Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study

OBJECTIVE: PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intoleran...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars Erik, Keiserman, Mauro, Papp, Kim, McCasland, Leslie, White, Douglas, Lu, Wenjing, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Behrens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234205/
https://www.ncbi.nlm.nih.gov/pubmed/36282530
http://dx.doi.org/10.1093/rheumatology/keac607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234205/
https://www.ncbi.nlm.nih.gov/pubmed/36282530
http://dx.doi.org/10.1093/rheumatology/keac607

Ejemplares similares